The names on this page are hidden. Create a free account to reveal 5 records a month, or get Private Equity Intelligence at $249 a month for every name. Every figure, date and source on this page is public either way.

Transactions / C•• L•••••••••

BroadOak Invests in C•• L•••••••••

Platform acquisitionannouncedannounced Jan 9, 2023Fact
What happened
Target
C•• L•••••••••
Platform
not an add-on on record
Control
Control
Share acquired
unknown
Industry
healthcare / laborator
Target location
unknown
Seller kind
unknown
Rollover
unknown
Values, only where disclosed
Enterprise value
Not disclosed
Purchase price
Not disclosed
Equity value
Not disclosed
Target revenue
Not disclosed
Target EBITDA
Not disclosed
Multiple
Not disclosed
Parties and roles
3 named
Buy side
  • A•••• F•••••Deal partnerconfirmed
    “Our investment will support the continued proliferation of their market-leading immune profiling technologies in research and clinical trials, and we look forward to working with CDI in their next phase of growth," said A•••• F•••••, Vice President at BroadOak Capital Partners.”
  • B••••••• A•••• M••••••••• L••Sponsorconfirmed
    “BroadOak Invests in C•• L••••••••• | published on B••••••• Asset's own news page broadoak.com”
Side not stated
Evidence
“BroadOak Invests in C•• L•••••••••”
Press release wires (PR Newswire, GlobeNewswire, Business Wire public pages and RSS)confidence 80%recorded Sep 18, 2026
BroadOak Invests in C•• L••••••••• | Private Equity Intelligence | DFX